Compare ARBE & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARBE | IMA |
|---|---|---|
| Founded | 2015 | 2019 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.3M | 66.3M |
| IPO Year | 2021 | 2021 |
| Metric | ARBE | IMA |
|---|---|---|
| Price | $0.32 | $3.82 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 4 |
| Target Price | $2.63 | ★ $18.00 |
| AVG Volume (30 Days) | ★ 808.6K | 14.3K |
| Earning Date | 11-19-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $800,000.00 |
| Revenue This Year | $301.71 | N/A |
| Revenue Next Year | $427.31 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.35 | $3.00 |
| 52 Week High | $1.94 | $7.60 |
| Indicator | ARBE | IMA |
|---|---|---|
| Relative Strength Index (RSI) | 27.34 | 47.97 |
| Support Level | N/A | N/A |
| Resistance Level | $0.91 | $4.37 |
| Average True Range (ATR) | 0.04 | 0.33 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 0.53 | 69.62 |
Arbe Robotics Ltd is a provider of 4D Imaging Radar solutions enabling driver-assist systems while paving the way for fully autonomous driving. It is a research and development company in the field of chips for Advanced radar systems, which are mainly intended to be used as Advanced Driver Assistance Systems (ADAS) adapted for autonomous vehicles, as well as for non-automotive uses. Geographically, the company generates maximum revenue from Sweden, and the rest from China, Hong Kong, the USA, Germany, Israel, and other markets.
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.